Warfarin discontinuation after starting warfarin for atrial fibrillation. - Test2 - elhamkhani - TriplyDB

Warfarin discontinuation after starting warfarin for atrial fibrillation.

Warfarin discontinuation after starting warfarin for atrial fibrillation.

http://www.wikidata.org/entity/Q34713428

about

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis.A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study.Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis.Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.Factors affecting time to maintenance dose in patients initiating warfarin.Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol.Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study.Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.Major vessel occlusion may predict subtherapeutic anticoagulation intensity and feasibility of administration of intravenous thrombolytics Efficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-analysis.Adherence to oral anticoagulant therapy in secondary stroke prevention - impact of the novel oral anticoagulants Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices.Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study.Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence Withdrawal of Antithrombotic Agents and the Risk of Stroke.Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care.Ablation of Atrial Fibrillation in the Elderly: Current Evidence and Evolving Trends.Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.Promise of factor Xa inhibition in atrial fibrillation.Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation.Personalizing oral anticoagulant treatment in patients with atrial fibrillation.Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.The caregiver role in thromboprophylaxis management in atrial fibrillation: a literature review.Target-specific oral anticoagulants: practice issues for the clinician.Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.Underuse of anticoagulation in patients with atrial fibrillation.Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?

P2860

Q26749141-D8D7FB15-505D-4607-BD5B-3D02793B9274 Q33828157-36C642CB-B037-4D79-BB7D-5663ABA0462F Q34150474-79B4A870-EC54-47EA-9899-EAA46FBDD129 Q34317469-232A9232-4FAE-4B69-BFDB-C1CF15767E36 Q34680367-8E92BBE0-4520-463E-BF80-9B36FBFE4E57 Q35239819-245F479A-8AF3-431A-8459-8A50A59E9E86 Q35792187-9263C2AE-4252-443B-BBE2-5D3D8E583AB5 Q36012558-33A1B4EF-2135-4CEF-A662-CFCB5044D99F Q36060109-12E9D487-9669-4E46-AFC9-116CF3C318BF Q36168742-811F1084-6298-49A5-879E-CFBF1D6FF127 Q36179688-8EC1A7F8-197B-40AA-8EEB-AA61E86F4125 Q36217719-2200B2A1-D877-4BFE-9A79-4EBFEF386AE1 Q36219093-7619276F-7E5E-49A3-A0AA-0692BE208051 Q36269672-46F95306-EF96-41F1-A4C7-2CC9116A1D7C Q36321564-6AF74A7A-91BE-4CEB-BABD-8BDEC691A5D6 Q36332351-48AF56CF-FAE3-42DF-8A60-173C8FDE1718 Q36344804-DBEF3349-A1A0-4797-B69D-5695ED902089 Q36352841-30FDC1E7-7123-481F-BEEA-F2B68F54C45B Q36551541-0E6E9B5B-0F0F-44DA-AABF-D0779B5CF775 Q36706241-E8CF202D-09E9-445E-9EB5-5FE915E4760B Q36714127-3BAA93A9-D318-47E5-8458-F6F7038D9898 Q36847664-667A1310-926C-40A8-9207-32FE714CBC71 Q37108889-EB275BED-CC5A-4FA8-A3D9-2B5918EC0F0F Q37201501-518610B1-A858-4CAA-B619-A37D07E442AA Q37240690-D32AF909-D1A0-482B-9A29-45B1ECBDC62F Q37312543-0CFAAFDA-6A78-40CE-B145-49A551A7CEEF Q37495744-00FCFBA3-2DDF-4442-9DBB-A7CF49A077F9 Q37868373-280168D5-3866-47D1-B60C-6ABB0F7D88E3 Q37959870-3E5ACF57-092F-489D-9A2E-57EE2AD354F9 Q38097727-77348E5F-A3D1-496D-BD7A-38055DEC719B Q38129965-84B0883E-4DE7-4C08-841C-85FE6309E43B Q38151988-BEA1897D-DD55-48EB-9A1C-92181FF1D32A Q38161519-719B86F4-800C-4FA1-810B-CF3D498DCE23 Q38240097-CFC31FC0-D18F-46CD-A33F-DAA222BD8C2E Q38254246-47C09E97-25C0-4AFD-82B8-F7421CAECF9B Q38602280-5C542A52-9A5C-475A-B023-6884A54F332B Q38655829-99B6CD09-E6E4-43B3-B24E-4C498D9859F1 Q38655951-8A844244-DC9E-41F1-B60D-37D660B10E82 Q38668964-0B52C1FE-7CE8-4B6D-AE0A-8CEAEA44EF49 Q38728028-691B8C3D-559D-44EC-908E-7463FC004480

P2860

Warfarin discontinuation after starting warfarin for atrial fibrillation.

http://www.wikidata.org/entity/Q34713428

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@ast

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@en

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@nl

type

label

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@ast

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@en

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@nl

prefLabel

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@ast

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@en

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@nl

P1433

Q34713428-C2438714-A09C-476D-9372-A3E27940D175

P1476

Q34713428-54DB559C-44BE-4AA9-BCA1-8051595F1CAB

P2093

Q34713428-1ABCB841-7EE3-4F7F-9067-B54D7410F5CD

Q34713428-684EF482-9E9F-4033-8F3F-735A5A643526

Q34713428-82B236A1-B8B1-43CF-ADF1-18F64992671B

Q34713428-9A2A5981-67B9-45C7-9649-8B055D821CE8

Q34713428-A124F490-DF0F-4FA5-B41D-38694AC8B95A

Q34713428-A5002FCB-2AF5-480F-B599-73F2B2348E66

Q34713428-DBF1BE1C-D616-4B57-AC85-6D4B0684A00D

P2860

Q34713428-15B140C7-BD3D-4B19-900B-67454B8EB724

Q34713428-1687BED9-B294-4C22-A810-8B79FBF74E4F

Q34713428-1E2667A9-0D17-4FA5-85A9-4D45C2720928

Q34713428-203FD2AC-567B-49AE-9632-06793DF02588

Q34713428-2A5458B6-02D2-4392-928E-FB930F82852D

Q34713428-314484DE-D8BF-4A20-8CDC-D3F01F26A59D

Q34713428-37C4FE2D-B960-46E1-B6DE-B84548747F4D

Q34713428-388233AF-9BF6-4D27-AF70-E363AA75004C

Q34713428-4A4F8744-9573-4E29-B8D7-1E94341D0AB9

Q34713428-581558C2-A6B1-4D6E-A8E1-B2405981559A

P304

Q34713428-E3F3425E-2043-4A34-B0A8-8323BE5FE8CB

P31

Q34713428-C38B39BE-854E-4A5F-A8AE-833D00F1F1A4

P356

Q34713428-B5B2E695-3A8E-47ED-8311-C50C54EBAD43

P433

Q34713428-FA8BFD98-44EA-42A7-9406-79D34367DD68

P478

Q34713428-833CBB8A-3880-47CA-AB3E-1D2AEC6E8F56

P577

Q34713428-475C11B8-589E-4817-BF94-BCCF4A69397E

P698

Q34713428-926A1758-B419-493F-8361-BECFFA913910

P921

Q34713428-43B852D3-C035-4E86-B164-411FA1A410AA

P932

Q34713428-E610DC6C-D7D3-43F8-A099-BDF2D7678B3C

P356

CIRCOUTCOMES.110.937680

P1433

Circulation: Cardiovascular Quality and Outcomes

P1476

Warfarin discontinuation after starting warfarin for atrial fibrillation.

@en

P2093

Alan S Go

http://www.w3.org/2001/XMLSchema#string

Daniel E Singer

http://www.w3.org/2001/XMLSchema#string

Leila H Borowsky

http://www.w3.org/2001/XMLSchema#string

Margaret C Fang

http://www.w3.org/2001/XMLSchema#string

Natalia Udaltsova

http://www.w3.org/2001/XMLSchema#string

Niela K Pomernacki

http://www.w3.org/2001/XMLSchema#string

Yuchiao Chang

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?

Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke

Antithrombotic therapy in atrial fibrillation

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

Validation of Clinical Classification Schemes for Predicting Stroke

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co

A comparison of rate control and rhythm control in patients with atrial fibrillation.

P304

624-631

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCOUTCOMES.110.937680

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20959565

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

3063305

http://www.w3.org/2001/XMLSchema#string